Based on these results, JAK2-mutated cancers feature enhanced cancer immunogenicity and a relatively hot immune microenvironment, strongly supporting the prognostic significance of JAK2 mutation for determining the response to ICI treatment. The gene discussed is JAK2; the disease is cancer.